Compliance Is Treated as a Blocker. It Should Be a Partner.

Compliance Is Treated as a Blocker. It Should Be a Partner.

One Idea Worth Acting On.

A cross-functional team finalizes a multi-million dollar commercialization strategy for a novel oncology therapy.

The plan is aggressive. The timeline is tight.

Days before execution, it lands on the Compliance desk for the first time.

Red flags. Materials pulled. Launch delayed.

The commercial team says Compliance is blocking innovation.

Compliance says the strategy was never designed to survive real-world execution.

Both are right.

What's Actually Happening

The "Department of No" framing is self-fulfilling. When organizations keep Compliance out of strategic conversations to protect speed, Compliance can only intervene at the end — after strategies are locked, budgets are committed, and timelines are set. At that point, any meaningful change is painful and expensive.

As Tina Clark Beamon, Chief Compliance Officer at Epikast and contributor to Voices of Oncology, explains: Legal answers the question "what can we do?" Compliance answers the equally important question "what should we do — and what happens if it goes wrong?"

Those are not the same question. And when only the first one is asked, organizations build strategies that are legally defensible and operationally fragile.

The exclusion of Compliance from early development is not limited to commercial activities. Publication planning, clinical trial design decisions, digital communications — all carry compliance implications that are far cheaper to manage at the design stage than at the correction stage.

Why This Matters

In oncology, the pressure to move fast is real. The competitive environment is intense, launch windows are narrow, and every delay has patient-level consequences.

But speed without integrity is not a competitive advantage. It is a liability with a delayed detonation.

The organizations that consistently launch on time are not the ones that treat Compliance as a late-stage reviewer. They are the ones that have embedded Compliance early enough that the late-stage review is a confirmation, not a correction.

Where It Breaks in the Real World

A promotional campaign is built, approved internally, and distributed before Compliance has reviewed the data claims. The claims are accurate. The presentation is misleading. By the time the issue surfaces — through a competitor complaint, an FDA inquiry, or a field observation — the materials have been in the market for weeks.

The correction costs more than the campaign. The reputational damage lasts longer than either.

The same pattern appears in medical education programs, advisory board designs, and speaker bureau structures — all built without Compliance input because the team assumed they knew where the lines were.

What Needs to Change

Compliance needs a defined seat at the strategy table — before the strategy is built, not after it is finished. That means a named Compliance liaison for every major commercial, medical, and development initiative, engaged at the design stage with the explicit mandate to say what will and will not survive real-world execution.

That is not a constraint on innovation. It is the infrastructure that makes innovation sustainable.

The Bottom Line

Compliance is not the finish line. It is the foundation.

The organizations that treat it as a late-stage hurdle will keep paying to fix strategies that could have been built right the first time.

Add Your Voice — Where are you seeing this? What's working — and what's not?